FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/New Phase 2 Study to Evaluate Vosoritide for Children with Idiopathic Short Stature
研究ライブラリに戻る

New Phase 2 Study to Evaluate Vosoritide for Children with Idiopathic Short Stature

May 25, 2026
Share
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、最近のニュースアイテムや臨床試験リストのAI補助要約です。ペプチド研究コミュニティにとって迅速でアクセスしやすい概要を提供することを目的としています。正確性のために常に下記リンク先の元のソースをご確認ください。

New Phase 2 Study to Evaluate Vosoritide for Children with Idiopathic Short Stature

A recent announcement on ClinicalTrials.gov details a new phase 2 clinical trial evaluating vosoritide, an investigational treatment aimed at addressing idiopathic short stature (ISS) in children. Sponsored by BioMarin Pharmaceutical, the study aims to assess both the efficacy and safety of multiple doses of vosoritide compared to human growth hormone (hGH), particularly for those residing in the United States.

Background

Idiopathic short stature is a condition where children experience significantly below-average height without any identifiable medical cause. This often leads to social, psychological, and physical challenges that can affect the child's quality of life. Currently, human growth hormone injections are a common treatment option, but they come with potential side effects and high costs. Vosoritide, a synthetic peptide, offers an alternative approach by targeting specific pathways involved in bone elongation.

This clinical trial will provide valuable insights into whether vosoritide could serve as an effective and safer long-term solution for children dealing with ISS. The study's inclusion of both placebo and active comparison groups will help researchers understand the true impact of vosoritide on growth patterns compared to existing treatments.

Key Details

The Phase 2 study, officially titled "A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature," is currently recruiting participants across various sites. It involves children aged between 5 and 18 years who have been diagnosed with ISS but show no signs of other conditions that might explain their short stature.

Participants will receive vosoritide injections daily for a period of up to one year, with regular monitoring sessions throughout the trial duration. The primary goal is to measure growth velocity over time using precise measurements such as height assessments and bone age determinations. Additional secondary objectives include evaluating safety profiles through blood tests, physical examinations, and adverse event reports.

In addition to vosoritide, some participants in the United States will be given human growth hormone (hGH) for direct comparison purposes. This multi-faceted approach aims at providing comprehensive data on efficacy, safety, and long-term benefits of vosoritide versus standard treatments currently available.

Key Takeaways

  • Clinical Trial Recruitment: The Phase 2 study is actively recruiting eligible children diagnosed with idiopathic short stature.
  • Comparative Analysis: Vosoritide will be compared against human growth hormone (hGH) in the United States, offering insights into relative effectiveness and safety profiles.
  • Long-term Monitoring: Participants will undergo rigorous monitoring over a year to assess long-term effects of vosoritide on growth patterns.
  • Patient Safety Focus: The study prioritizes patient safety through regular health checks and adverse event reporting mechanisms.

What This Means

For the peptide research community, this trial represents a significant step forward in exploring alternative treatments for idiopathic short stature. If vosoritide proves to be an effective and safer option compared to human growth hormone, it could revolutionize how pediatricians manage ISS cases going forward. The potential implications for FDA regulation and future clinical applications are considerable, opening new avenues for peptide therapy development.

Moreover, the study's focus on long-term efficacy and safety provides critical data points that could influence healthcare policies and patient care strategies related to growth disorders in children. By shedding light on novel treatment pathways, this research contributes valuable knowledge to both scientific understanding and practical medical practice.

---

Source: ClinicalTrials.gov — Published 2026-05-22

This article is for informational purposes only and does not constitute medical advice.

編集者の注

この分析はAIツールを使用して生成され、Peptide Contacts編集部がレビューしました。正確性を追求していますが、AI生成のコンテンツには誤りや省略がある可能性があります。情報確認のために常に元のソースをご確認ください。 元のソース 詳細、方法論、データについては

Peptide Contactsは、情報提供のために-curated研究要約を提供しています。このコンテンツは医療アドバイスにはなりません。健康決定をする前に常に格付けされた医療専門家に相談してください。

Comments

Sign in to join the discussion

この記事はAIを使用して生成され、誤りや省略がある可能性があります。情報提供のために提供されていますが、医療アドバイスにはなりません。常に元のソースを確認し、格付けされた医療専門家に相談してください。